Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

This is a Phase Ib clinical study conducted in China to evaluate the treatment of advanced non-small cell lung cancer with JSKN016 in combination therapy. The enrolled subjects are all in the locally advanced or metastatic stage of non-small cell lung cancer.

Trial Details

NCT ID

NCT06868732

Phase

PHASE1

Sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

JSKN016
Carboplatin
Furmonertinib Mesylate
Ivonescimab
Docetaxel
Tislelizumab

Locations (sample)

Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

Voluntarily participate and sign the informed consent form.
Age ≥ 18 years old, ≤ 75 years old, male or female.
Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.
Expected survival ≥ 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →